The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

Goldman Sachs believes that Biohaven offers investors an under-the-radar opportunity to invest in a potentially best-in-class ...

Biotech stocks rebounded in 2025. Wedbush’s Laura Chico explains why rare disease catalysts and upcoming data could shape the ...

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

Biotech investors often chase early-stage companies in the hope that a single breakthrough trial will deliver massive returns ...

In a 2026 market where investors are cautiously rotating toward quality amid lingering macro uncertainty, below is a list of ...

Will this biotech's innovative platform finally pay off?

Healthcare stocks rebounded in 2025. These three healthcare growth stocks offer exposure to innovation beyond traditional ...

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, ...

Artificial intelligence (AI) isn't the only industry with explosive growth potential.